Le Lézard
Classified in: Health
Subjects: TRI, MIN

PLT Health Solutions Granted Broad Ranging Cognitive Health Claims from Health Canada Based on Clinical Study Results


Nutricog® Cognitive Performance Complex has been Clinically Demonstrated to Improve Memory, Increase Learning Rate and Capacity, Enhance Focus and Concentration and Improve Overall Brain Function

MORRISTOWN, N.J., April 29, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that it has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient Nutricog® Cognitive Performance Complex to support cognitive health in Canada. Nutricog  is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) ? standardized to gallic acid, ellagic acid and amyrins. In a randomized, double-blind, placebo-controlled clinical trial, users of Nutricog demonstrated significant improvements compared to placebo across multiple cognitive domains, including learning, memory, sustained attention, working memory and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking.

The list of claims approved by Health Canada for Nutricog include:

According to Seth Flowerman, President and CEO of PLT Health Solutions, the granting of an NHP license for Nutricog by Health Canada is significant for what it says about the science that supports Nutricog. "The broad range of cognitive performance benefits demonstrated in our clinical study make it ideal to support memory products, focus and attention products, general brain products and more. Health Canada has a high bar for clinically supported health claims, and we are proud of the quality of science supporting this innovative and breakthrough ingredient," he added.

Studies demonstrate broad-ranging cognitive support

A randomized, double-blind, placebo-controlled clinical trial assessed Nutricog for its ability to impact learning and memory, including attention, working memory, and decision-making. 100 healthy male and female subjects, aged 40-65 years, were provided 120 days of daily Nutricog or placebo and assessed for performance improvements on the Rey Auditory Verbal Learning Test (RAVLT) and the Cambridge Neuropsychological Test Automated Battery (CANTAB), both well-established and validated tools used to evaluate learning, memory, and other aspects of cognitive performance. Other measures included the Athens Insomnia Scale and biomarker testing for Brain-derived Neurotrophic Factor (BDNF).

Improvements in cognitive performance reported out from the study included:

^ These outcomes were statistically significant compared to placebo in the clinical study

According to Jeremy Appleton, ND, Director of Medical and Scientific Affairs PLT Health Solutions, the broad range of benefits seen with the Nutricog clinical trial suggests a wide range of products into which it can be formulated. "The power of these clinical results is not just that Nutricog showed significance in such a broad array of areas, but the amount of change versus placebo that was demonstrated," he said. "The market size and potential for knowledge workers alone?that includes over 100 million people? speaks to huge number of people who can benefit from this ingredient," he added.

People of all age groups are tuning into the benefits of improved cognitive health and performance The cognitive health supplement market in the United States alone is expected to grow at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2033, reaching a valuation of US$16.8 billion by 2033

For more information on this ingredient, visit www.plthealth.com/nutricog.

* THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

Media Contact:
Mark Falconer
Sciencewerks
Voice: 407-412-9705
E-mail: [email protected] 

Company Contact:  Steve Fink
PLT Health Solutions, Inc.
Voice: 973-984-0900 x214
E-mail: [email protected]

SOURCE PLT Health Solutions


These press releases may also interest you

at 23:20
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

at 23:07
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

at 21:03
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

at 21:00
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

at 20:54
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...



News published on and distributed by: